Get the Stockscreener App
358.93
2.04%
-7.46
After Hours:
365.00
6.07
+1.69%
United Therapeutics Corp stock is traded at $358.93, with a volume of 242.93K.
It is down -2.04% in the last 24 hours and down -5.47% over the past month.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
See More
Previous Close:
$366.39
Open:
$372.34
24h Volume:
242.93K
Relative Volume:
0.79
Market Cap:
$16.02B
Revenue:
$2.76B
Net Income/Loss:
$1.11B
P/E Ratio:
15.76
EPS:
22.77
Net Cash Flow:
$898.10M
1W Performance:
-1.65%
1M Performance:
-5.47%
6M Performance:
+8.29%
1Y Performance:
+61.50%
1-Day Range:
$357.25
$372.34
1-Week Range:
$357.25
$372.34
52-Week Range:
$208.62
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Industry
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
358.93 | 16.02B | 2.76B | 1.11B | 898.10M | 22.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Manchester gets offer from United Therapeutics to buy nearly 350 acres in Hackett Hill area - AOL
United Therapeutics Corporation (NASDAQ:UTHR) Doing What It Can To Lift Shares - Simply Wall St
Wedge Capital Management L L P NC Has $28.03 Million Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Assenagon Asset Management S.A. Sells 8,067 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
USA Financial Formulas Has $307,000 Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Upgraded to Strong-Buy at StockNews.com - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Short Interest Update - MarketBeat
Wedmont Private Capital Acquires Shares of 1,276 United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
UTHR: 3 Niche Biotech Stocks Redefining Innovation - StockNews.com
Burney Co. Raises Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,646,200.00 in Stock - MarketBeat
United Therapeutics president sells $3.65 million in stock By Investing.com - Investing.com Australia
United Therapeutics president sells $3.65 million in stock - Investing.com India
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.
United Therapeutics to Present at J.P. Morgan Conference - TipRanks
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Nordea Investment Management AB - MarketBeat
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance
Here's Why United Therapeutics (UTHR) is a Strong Value Stock - Yahoo Finance
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year? - Yahoo Finance
7 Best Biotech Stocks to Buy for 2025 | Investing - U.S News & World Report Money
United Therapeutics president Michael Benkowitz sells $3.55 million in stock By Investing.com - Investing.com Australia
United Therapeutics president Michael Benkowitz sells $3.55 million in stock - Investing.com India
United Therapeutics snaps up another property near Silver Spring HQ - The Business Journals
CWA Asset Management Group LLC Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics CEO to Present Business Update at J.P. Morgan Healthcare Conference - StockTitan
JPMorgan Chase & Co. Has $69 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Corp - GuruFocus.com
Nilda Mesa Sells 255 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics president Michael Benkowitz sells $3.57 million in stock By Investing.com - Investing.com Canada
United Therapeutics director Mesa Nilda sells $90,720 in stock By Investing.com - Investing.com Nigeria
United Therapeutics director Mesa Nilda sells $90,720 in stock - Investing.com India
United Therapeutics president Michael Benkowitz sells $3.57 million in stock - Investing.com
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease - Yahoo Finance
United Therapeutics Corporation (UTHR): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 - Insider Monkey
United Therapeutics president Michael Benkowitz sells $3.6m in stock - Investing.com India
Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) COO Sells 10,000 Shares of Stock - MarketBeat
United Therapeutics president Michael Benkowitz sells $3.6m in stock By Investing.com - Investing.com UK
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term - Yahoo Finance
Here are Updates on United Therapeutics Corp. (UTHR) - MSN
Is United Therapeutics (UTHR) the Best Performing Biotech Stock in 2024? - Yahoo Finance
Principal Financial Group Inc. Has $40.31 Million Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term - Yahoo Finance
Insider Sell: Louis Sullivan Sells 26,209 Shares of United Thera - GuruFocus.com
United Therapeutics Co. (NASDAQ:UTHR) Director Sells $9,781,722.98 in Stock - MarketBeat
United Therapeutics director sells shares worth $9.78 million - Investing.com
United Therapeutics president and COO sells $3.7 million in stock - Investing.com India
United Therapeutics (NASDAQ:UTHR) Trading Down 4.4%Here's Why - MarketBeat
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.62%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):